We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+17%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.33B
AUM Growth
+$1.78B
(+24%)
Cap. Flow
+$552M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
20.52%
Holding
814
New
78
Increased
378
Reduced
271
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$50.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$39.4M |
| 3 |
Intel
INTC
|
+$29.2M |
| 4 |
Qualcomm
QCOM
|
+$27.6M |
| 5 |
Danaher
DHR
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$49.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$41.6M |
| 3 |
ARQL
Arqule Inc
ARQL
|
+$26.5M |
| 4 |
Arrowhead Research
ARWR
|
+$24.9M |
| 5 |
Merck
MRK
|
+$15.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.73% |
| 2 | Technology | 19.55% |
| 3 | Financials | 10.18% |
| 4 | Consumer Discretionary | 9.32% |
| 5 | Communication Services | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Humana
HUM
$46.7B
| $14.5M | 0.16% |
39,683
+25,865
| +187% | +$8.2M |
|
152
Prologis
PLD
$138B
| $14.5M | 0.16% |
163,088
+7,315
| +5% | +$648K |
|
153
PACCAR
PCAR
$69.6B
| $14.5M | 0.16% |
275,198
+95,231
| +53% | +$4.9M |
|
154
Halozyme
HALO
$9.72B
| $14.5M | 0.15% |
815,272
+168,193
| +26% | +$2.91M |
|
155
DuPont de Nemours
DD
$18.6B
| $14.3M | 0.15% |
177,822
+101,626
| +133% | +$8.44M |
|
156
Fortinet
FTNT
$112B
| $14.3M | 0.15% |
668,000
-297,540
| -31% | -$5.6M |
|
|
HOLI
157
DELISTED
Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island)
HOLI
| $14M | 0.15% |
850,519
+44,496
| +6% | +$675K |
|
158
Stanley Black & Decker
SWK
$14.2B
| $13.9M | 0.15% |
83,718
+57,515
| +219% | +$8.91M |
|
159
Varonis Systems
VRNS
$5.25B
| $13.8M | 0.15% |
533,976
-99,993
| -16% | -$2.37M |
|
160
PVH
PVH
$3.71B
| $13.8M | 0.15% |
131,047
+91,557
| +232% | +$8.74M |
|
161
NeoGenomics
NEO
$1.81B
| $13.6M | 0.15% |
466,584
+206,383
| +79% | +$4.91M |
|
162
SLB Ltd
SLB
$77.8B
| $13.6M | 0.15% |
337,968
-203,594
| -38% | -$7.27M |
|
|
AMRN
163
Amarin Corp
AMRN
$284M
| $13.5M | 0.15% |
31,550
+550
| +2% | +$209K |
|
|
EE
164
DELISTED
El Paso Electric Company
EE
| $13.4M | 0.14% |
+197,148
| New | +$13.3M |
|
|
MDCO
165
DELISTED
Medicines Co
MDCO
| $13.3M | 0.14% |
157,106
-124,394
| -44% | -$8.3M |
|
166
Azenta
AZTA
$1.26B
| $13.2M | 0.14% |
314,046
-23,393
| -7% | -$983K |
|
167
Darden Restaurants
DRI
$22.5B
| $13.1M | 0.14% |
120,358
+35,492
| +42% | +$4.03M |
|
168
Silicon Laboratories
SLAB
$7.15B
| $12.9M | 0.14% |
111,533
+639
| +0.6% | +$70.1K |
|
|
ESPR
169
DELISTED
Esperion Therapeutics
ESPR
| $12.8M | 0.14% |
+215,096
| New | +$9.67M |
|
|
MRTX
170
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $12.8M | 0.14% |
99,323
-22,977
| -19% | -$2.22M |
|
|
VMW
171
DELISTED
VMware, Inc
VMW
| $12.8M | 0.14% |
84,184
+39,728
| +89% | +$6.23M |
|
172
United Parcel Service
UPS
$97.6B
| $12.7M | 0.14% |
108,260
+14,669
| +16% | +$1.74M |
|
173
Microchip Technology
MCHP
$42.8B
| $12.7M | 0.14% |
241,590
+21,432
| +10% | +$1.04M |
|
174
CVS Health
CVS
$137B
| $12.5M | 0.13% |
168,398
+17,700
| +12% | +$1.24M |
|
|
WCG
175
DELISTED
Wellcare Health Plans, Inc.
WCG
| $12.5M | 0.13% |
37,770
+8,160
| +28% | +$2.45M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2019 Portfolio in Review
As of Q4 2019, Candriam SCA held 814 positions worth $9.33B, up 24% from $7.55B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA deployed $552M of net new capital in Q4 2019, opening 78 new positions and adding to 378 existing holdings. Its largest new stake was Vipshop: 2,005,000 shares worth $28.4M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Ra Pharmaceuticals, Inc. Common Stock, an estimated $49.9M trimmed.
- Candriam SCA's largest Q4 2019 buy was Vipshop: 2,005,000 shares worth $28.4M.
- Candriam SCA added most to Microsoft in Q4 2019, an estimated $50.3M increase.
- Candriam SCA's biggest Q4 2019 reduction was Ra Pharmaceuticals, Inc. Common Stock, cutting an estimated $49.9M.
- Candriam SCA fully exited Hilton Worldwide in Q4 2019, selling an estimated $11.8M.
- Candriam SCA's ten largest holdings make up 21% of its $9.33B portfolio in Q4 2019.
- Candriam SCA opened 78 new positions and closed 33 in Q4 2019.
- Candriam SCA's portfolio value rose 24% quarter-over-quarter to $9.33B.
Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.